Synergy Pharmaceuticals Company

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.
Technology: Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Industry: Early Drug Development
Headquarters: New York, New York, United States
Founded Date: 1992-02-11
Employees Number: 101-250
Funding Status: IPO
Investors Number: 1
Total Funding: 407231243
Estimated Revenue: $10M to $50M
Last Funding Date: 2017-09-05
Last Funding Type: Post-IPO Debt

Visit Website
info@synergypharma.com
http://twitter.com/synergypharma
Register and Claim Ownership